Do you want to read an article? Please log in or register.
A product review of vedolizumab in inflammatory bowel disease
Inflammatory Bowel Disease
Related content
Inflammatory Bowel Disease
Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases
Inflamm Bowel Dis.
Attauabi M, Zhao M, Bendtsen F, Burisch J
doi: 10.1093/ibd/izaa167.
Inflammatory Bowel Disease
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice
Biologicals.
Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T
doi: 10.1016/j.biologicals.
Inflammatory Bowel Disease
Disease-Associated Costs in Children With Inflammatory Bowel Disease: A Systematic Review
Inflamm Bowel Dis.
El-Matary W, Kuenzig ME, Singh H, Okoli G, Moghareh M, Kumar H, Lê ML, Benchimol EI
doi: 10.1093/ibd/izz120.
Inflammatory Bowel Disease
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Aliment Pharmacol Ther.
Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group
doi: 10.1111/apt.14930.
Inflammatory Bowel Disease
Postoperative Outcomes in Vedolizumab-Treated Patients Undergoing Major Abdominal Operations for Inflammatory Bowel Disease: Retrospective Multicenter Cohort Study
Inflamm Bowel Dis.
Lightner AL, Mathis KL, Tse CS, Pemberton JH, Shen B, Kochlar G, Singh A, Dulai PS, Eisenstein S, Sandborn WJ, Parry L, Stringfield S, Hudesman D, Remzi F, Loftus EV Jr
doi: 10.1093/ibd/izx076.
Inflammatory Bowel Disease
Vedolizumab in the perioperative management of inflammatory bowel disease
Curr Drug Targets.
Lightner AL, Loftus EV, McKenna NP, Raffals LE
doi: 10.2174/
Inflammatory Bowel Disease
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review
J Crohns Colitis.
Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L
doi: 10.1093/ecco-jcc/jjz095.
Inflammatory Bowel Disease
Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study
Therap Adv Gastroenterol.
Grob L, Bluemel S, Biedermann L, Fournier N, Rossel JB, Vavricka SR, Zeitz J, Rogler G, Stallmach A, Scharl M
doi: 10.1177/1756284819895217.
RECOMMENDED
Inflammatory Bowel Disease
Inflammatory cutaneous lesions in inflammatory bowel disease treated with Vedolizumab or Ustekinumab: an ECCO CONFER multicentre case series
★ 1
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
doi: 10.1093/ecco-jcc/jjaa078.